Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
NCT ID: NCT01435525
Last Updated: 2014-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
369 participants
OBSERVATIONAL
2011-09-30
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
NCT02249546
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
NCT01572597
The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.
NCT03583476
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05237115
Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection
NCT03521726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nexium
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer
* Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma
* Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura
* Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shigeru Yoshida, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aichi, , Japan
Research Site
Akita, , Japan
Research Site
Chiba, , Japan
Research Site
Ehime, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukushima, , Japan
Research Site
Gifu, , Japan
Research Site
Gunma, , Japan
Research Site
Hiroshima, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hyōgo, , Japan
Research Site
Ibaraki, , Japan
Research Site
Kagawa, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kochi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kyoto, , Japan
Research Site
Mie, , Japan
Research Site
Miyagi, , Japan
Research Site
Nagano, , Japan
Research Site
Nagasaki, , Japan
Research Site
Niigata, , Japan
Research Site
Numakunai, , Japan
Research Site
Okayama, , Japan
Research Site
Okinawa, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Saitama, , Japan
Research Site
Shiga, , Japan
Research Site
Shimane, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tokyo, , Japan
Research Site
Toyama, , Japan
Research Site
Wakayama, , Japan
Research Site
Yamagata, , Japan
Research Site
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D961HC00011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.